Sana Biotechnology SANA, a clinical-stage company, is expected to report its fourth-quarter results soon. The company leverages its proprietary hypoimmune technology to develop cell engineering programs for treating type 1 diabetes (T1D), B-cell-mediated autoimmune diseases and oncology indications.
See the Zacks Earnings Calendar to stay ahead of market-making news.
The Zacks Consensus Estimate for SANA’s loss per share in the to-be-reported quarter is currently pegged at 25 cents. The company currently does not generate any revenues.
Let's see how things have shaped up for the upcoming quarterly release.
In the absence of a marketed product, investors are advised to look forward to the company’s pipeline updates in the upcoming earnings call.
Last month, Sana Bio announced positive initial results from a potentially groundbreaking T1D study of its experimental cell therapy, UP421. Notably, in the investigator-sponsored, first-in-human study, UP421 was transplanted into a patient with T1D without the use of any immunosuppression. UP421 is being developed in partnership with Uppsala University Hospital.
The study results were evaluated four weeks after intramuscular cell transplantation, confirming pancreatic beta cells' survival and functionality in the first treated T1D patient. The results were supported by the presence of circulating C-peptide, a biomarker indicating insulin production by the transplanted beta cells.
In the past three months, SANA shares have gained 17.6% against the industry’s 2% decline.
Sana Bio is trying to revolutionize the market for T1D treatments using primary islet cell transplantation. It aims to eliminate the need for immunosuppression by preventing both allogeneic and autoimmune rejection.
Currently, the study continues to evaluate the safety, persistence and function of transplanted cells in the treated T1D patient. Investors can expect an update from the company on the upcoming earnings call.
Sana Bio’s clinical pipeline comprises two other candidates, SC291 and SC262, which are being developed in separate early-stage studies, GLEAM and VIVID, for a variety of autoimmune and oncology indications, respectively. Updates from these studies are also expected in the fourth-quarter earnings release.
Research and Development expenses are likely to have declined in the to-be-reported quarter primarily due to lower personnel-related and laboratory costs following workforce reductions and reduced research expenditures, as part of the company's strategic repositioning, in 2023.
General and Administrative expenses are expected to decline in the upcoming quarterly release due to reduced costs from Sana Bio’s canceled Fremont facility, lower legal and consulting fees, and decreased personnel expenses due to a smaller workforce.
Sana Bio has a mixed earnings surprise history. It beat estimates in two of the trailing four quarters and missed on the other two occasions, delivering an average negative surprise of 3.98%. In the last reported quarter, the company came up with an earnings surprise of 3.85%.
Our proven model does not predict an earnings beat for Sana Bio this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. However, that is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
SANA’s Earnings ESP: SANA has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 25 cents per share.
SANA’s Zacks Rank: SANA currently carries a Zacks Rank #3.
argenx ARGX has an Earnings ESP of +29.90% and sports a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
ARGX’s shares have gained 3.1% in the past three months. argenx beat on earnings in two of the trailing four quarters and missed the mark on the other two occasions, delivering an average surprise of 339.37%.
Pacira BioSciences, Inc. PCRX has an Earnings ESP of +2.34% and sports a Zacks Rank #1 at present.
Shares of PCRX have surged 50.5% in the past three months. PCRX beat earnings estimates in two of the trailing four quarters, met once, and missed the same on the remaining occasion, delivering an average surprise of 7.13%.
Mirum Pharmaceuticals, Inc. MIRM has an Earnings ESP of +37.50% and a Zacks Rank #2 at present.
Shares of MIRM have surged 12.8% in the past three months. MIRM beat on earnings in one of the trailing four quarters while missing the same in the remaining three occasions, delivering an average negative surprise of 26.03%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pacira BioSciences, Inc. (PCRX) : Free Stock Analysis Report
argenex SE (ARGX) : Free Stock Analysis Report
Mirum Pharmaceuticals, Inc. (MIRM) : Free Stock Analysis Report
Sana Biotechnology, Inc. (SANA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。